BLFS (BioLife Solutions) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


BLFS BioLife Solutions Inc BLFS
72 GF Score
Price $28.64
GF Value $28.57
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioLife Solutions's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BLFS vs KMTS, AZTA, ATRC: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLife Solutions Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Margin of Safety % (DCF Earnings Based) falls into.


BLFS
72GF Score
BioLife Solutions Inc BLFS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score

Get the complete analysis for BLFS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.64
Price
$28.57
GF Value